[Buprenorphine treatment during pregnancy--risk factors and advantages need to be considered carefully].
Strengell
Paula
P
TAYS:n yleissairaalapsykiatrian klinikka, päihdepoliklinikan vauvaperheyksikkö, Tampere. paula.strengell@pshp.fi
Vahtola
Maria
M
Tammela
Outi
O
Seppä
Kaija
K
D000701:Analgesics, Opioid / Q000009:adverse effects* / Q000627:therapeutic use; D002047:Buprenorphine / Q000009:adverse effects* / Q000627:therapeutic use; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005387:Finland; D005500:Follow-Up Studies; D005865:Gestational Age; D006801:Humans; D008991:Monitoring, Physiologic / Q000379:methods; D010146:Pain / Q000175:diagnosis / Q000188:drug therapy*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000139:chemically induced* / Q000517:prevention & control; D011256:Pregnancy Outcome; D018570:Risk Assessment
D000701:Analgesics, Opioid; D002047:Buprenorphine